José Luis Manzano Mozo

Closest collaborators

The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Fernando Rivera Herrero · 2 shared papers, 2017–2020 · strength 0.13
   • Paper Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label… DOI 10.1016/s2468-1253(19)30327-9↗
   • Paper Gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in the first-line treatment of patients with metastatic… DOI 10.1016/j.ejca.2016.12.032↗
2. Roberto Pazo-Cid · 2 shared papers, 2017–2020 · strength 0.13
   • Paper Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label… DOI 10.1016/s2468-1253(19)30327-9↗
   • Paper Gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in the first-line treatment of patients with metastatic… DOI 10.1016/j.ejca.2016.12.032↗
3. Ruth Vera · 2 shared papers, 2016–2017 · strength 0.11
   • Paper SEOM Clinical Guideline for the treatment of pancreatic cancer (2016). DOI 10.1007/s12094-016-1586-x↗
   • Paper Gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in the first-line treatment of patients with metastatic… DOI 10.1016/j.ejca.2016.12.032↗
4. Teng Jin Ong · 1 shared paper, 2020 · strength 0.08
   • Paper Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label… DOI 10.1016/s2468-1253(19)30327-9↗
5. Christophe Borg · 1 shared paper, 2020 · strength 0.08
   • Paper Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label… DOI 10.1016/s2468-1253(19)30327-9↗
6. Edward Jae-Hoon Kim · 1 shared paper, 2020 · strength 0.08
   • Paper Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label… DOI 10.1016/s2468-1253(19)30327-9↗
7. Fabienne Portales · 1 shared paper, 2020 · strength 0.08
   • Paper Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label… DOI 10.1016/s2468-1253(19)30327-9↗
8. Muhammad Wasif Saif · 1 shared paper, 2020 · strength 0.08
   • Paper Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label… DOI 10.1016/s2468-1253(19)30327-9↗
9. Jill Lacy · 1 shared paper, 2020 · strength 0.08
   • Paper Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label… DOI 10.1016/s2468-1253(19)30327-9↗
10. Pascal R. Hammel · 1 shared paper, 2020 · strength 0.08
    • Paper Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label… DOI 10.1016/s2468-1253(19)30327-9↗
11. Philip A. Philip · 1 shared paper, 2020 · strength 0.08
    • Paper Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label… DOI 10.1016/s2468-1253(19)30327-9↗
12. Berta Laquente · 1 shared paper, 2016 · strength 0.06
    • Paper SEOM Clinical Guideline for the treatment of pancreatic cancer (2016). DOI 10.1007/s12094-016-1586-x↗
13. Mercedes Salgado · 1 shared paper, 2016 · strength 0.06
    • Paper SEOM Clinical Guideline for the treatment of pancreatic cancer (2016). DOI 10.1007/s12094-016-1586-x↗
14. Joan Maurel Santasusana · 1 shared paper, 2016 · strength 0.06
    • Paper SEOM Clinical Guideline for the treatment of pancreatic cancer (2016). DOI 10.1007/s12094-016-1586-x↗
15. Jaime Feliú · 1 shared paper, 2016 · strength 0.06
    • Paper SEOM Clinical Guideline for the treatment of pancreatic cancer (2016). DOI 10.1007/s12094-016-1586-x↗
16. Teresa Mercade Macarulla · 1 shared paper, 2016 · strength 0.06
    • Paper SEOM Clinical Guideline for the treatment of pancreatic cancer (2016). DOI 10.1007/s12094-016-1586-x↗
17. Joaquina Martínez-Galán · 1 shared paper, 2017 · strength 0.05
    • Paper Gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in the first-line treatment of patients with metastatic… DOI 10.1016/j.ejca.2016.12.032↗
18. Manuel Benavides · 1 shared paper, 2017 · strength 0.05
    • Paper Gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in the first-line treatment of patients with metastatic… DOI 10.1016/j.ejca.2016.12.032↗
19. Marta Martín-Richard · 1 shared paper, 2017 · strength 0.05
    • Paper Gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in the first-line treatment of patients with metastatic… DOI 10.1016/j.ejca.2016.12.032↗
20. Javier Gallego-Plazas · 1 shared paper, 2017 · strength 0.05
    • Paper Gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in the first-line treatment of patients with metastatic… DOI 10.1016/j.ejca.2016.12.032↗
21. Carmen Guillén‐Ponce · 1 shared paper, 2017 · strength 0.05
    • Paper Gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in the first-line treatment of patients with metastatic… DOI 10.1016/j.ejca.2016.12.032↗
22. Antonio Irigoyen · 1 shared paper, 2017 · strength 0.05
    • Paper Gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in the first-line treatment of patients with metastatic… DOI 10.1016/j.ejca.2016.12.032↗
23. Enrique Aranda Aguilar · 1 shared paper, 2017 · strength 0.05
    • Paper Gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in the first-line treatment of patients with metastatic… DOI 10.1016/j.ejca.2016.12.032↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.